Section 6: Education and Research

6ER-016

IDENTIFICATION OF NEW GENES OF EARLY RESPONSE TO ANTI-TNFS BY RNASEQ IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.

6ER-015

AZACITIDINE IN THE TREATMENT OF JUVENILE MYELOMONOCYTIC LEUKAEMIA: AN UP-TO-DATE PHARMACY PROTOCOL

6ER-014

EFFECTIVENESS AND SAFETY OF THE ADMINISTRATION OF MURPHY’S ENEMA FOR THE TREATMENT OF REFRACTORY CONSTIPATION IN A TERTIARY HOSPITAL

6ER-013

1 YEAR-MORTALITY RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.

6ER-012

TREATMENT DECISIONS ACCORDING TO 1-YEAR RISK MORTALITY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.

6ER-011

EFFICACY OF THERAPIES IN NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS: A SYSTEMATIC REVIEW

6ER-010

EVOLUTION OF ONCOHAEMATOLOGICAL CLINICAL TRIALS FROM 2016 TO 2021: EXPERIENCE FROM A TERTIARY HOSPITAL

6ER-009

COMPARATIVE EFFICACY OF ABEMACICLIB AND PALBOCICLIB AS ADJUVANT TREATMENT IN PATIENTS WITH EARLY BREAST CANCER

6ER-008

CORRELATES OF ONE-YEAR MORTALITY AMONG PATIENTS LIVING WITH HIV ACCORDING TO THE STRATIFICATION LEVEL OF THE PHARMACEUTICAL CARE MODEL

6ER-007

PHYSICO-CHEMICAL PARAMETERS OF TOBACCO OIL AND PREPARATION OF A DOSAGE FORM BASED ON IT

6ER-006

CURRENT PERFORMANCE OF HOSPITAL PHARMACY SPECIALISTS TRAINED AT A TERTIARY HOSPITAL IN SPAIN

6ER-005

EFFECTS OF ADHERENCE TO THE MEDITERRANEAN DIET IN PATIENTS WITH AUTOIMMUNE DISEASES

6ER-004

EFFECTIVENESS AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED DISEASES ON BIOLOGICAL THERAPY

6ER-003

THE CLIMATE EMERGENCY, HOW CAN PHARMACY MAKE A DIFFERENCE?

6ER-002

WHAT's ANOTHER PEER? EXPLORING THE USE OF NEAR PEER TEACHING OF MEDICATION HISTORY TAKING IN PHARMACY UNDERGRADUATES IN THE UK

Pages